XML 46 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Capital Stock
 12 Months Ended
Dec. 31, 2022
Share Capital and Share-based Payment Arrangements [Abstract]  
Capital Stock CAPITAL STOCK:
We are authorized to issue an unlimited number of SVS, which entitle the holder to one vote per share, and an unlimited number of multiple voting shares (MVS), which entitle the holder to 25 votes per share. The SVS and MVS vote together as a single class on all matters submitted to a vote of shareholders, including the election of directors, except as otherwise required by law. The holders of the SVS and MVS are entitled to share ratably, as a single class, in any dividends declared subject to any preferential rights of any outstanding preferred shares in respect of the payment of dividends. Each MVS is convertible at any time at the option of the holder thereof and automatically, under certain circumstances, into one SVS. We are also authorized to issue an unlimited number of preferred shares, issuable in series. No preferred shares have been issued to date.
(a) Capital transactions:
Number of shares (in millions)SVSMVS
Issued and outstanding at December 31, 2019110.2 18.6 
Issued from treasury(i)
0.3 — 
Cancelled under normal course issuer bid (NCIB)(0.0062)— 
Issued and outstanding at December 31, 2020110.5 18.6 
Issued from treasury(i)
0.03 — 
Cancelled under NCIB(4.37)— 
Issued and outstanding at December 31, 2021106.1 18.6 
Issued from treasury(i)
0.07 — 
Cancelled under NCIB(3.14)— 
Issued and outstanding at December 31, 2022103.0 18.6 
(i)     In 2022, 0.02 million SVS (2021 — 0.02 million; 2020 — nil) were issued from treasury upon the exercise of stock options for aggregate cash proceeds of $0.2 (2021 — $0.2; 2020 - nil). In 2022, we issued 0.05 million (2021 — 0.01 million; 2020 — 0.3 million) SVS from treasury with an ascribed value of $0.4 (2021 — $0.1; 2020 — $2.2) upon the vesting of certain RSUs and PSUs. We settled other RSUs and PSUs with SVS purchased in the open market (described below).
We have repurchased SVS in the open market, or as otherwise permitted, for cancellation through NCIBs, which allow us to repurchase a limited number of SVS during a specified period. The maximum number of SVS we are permitted to repurchase for cancellation under each NCIB is reduced by the number of SVS we arrange to be purchased by any non-independent broker in the open market during the term of such NCIB to satisfy delivery obligations under our SBC plans. We from time-to-time enter into automatic share purchase plans (ASPPs) with a broker, instructing the broker to purchase our SVS in the open market on our behalf, either for cancellation under an NCIB (NCIB ASPPs) or for delivery obligations under our SBC plans (SBC ASPPs), including during any applicable trading blackout periods, up to specified maximums (and subject to certain pricing and other conditions) through the term of each ASPP.
On November 19, 2020, the TSX accepted our notice to launch an NCIB (2020 NCIB), which allowed us to repurchase, at our discretion, from November 24, 2020 until the earlier of November 23, 2021 or the completion of purchases thereunder, up to approximately 9.0 million SVS in the open market, or as otherwise permitted, subject to the normal terms and limitations of such bids. We entered into NCIB ASPPs in each of December 2020, March 2021, and June 2021, all of which have since expired. At December 31, 2020, we recorded an accrual of $15.0 (2020 NCIB Accrual), representing the estimated contractual maximum number of permitted SVS repurchases (Contractual Maximum Quantity) for cancellation under the December 2020 NCIB ASPP (2.0 million SVS), which was reversed in 2021.
    On December 2, 2021, the TSX accepted our notice to launch another NCIB (2021 NCIB), which allowed us to repurchase, at our discretion, from December 6, 2021 until the earlier of December 5, 2022 or the completion of purchases thereunder, up to approximately 9.0 million of our SVS in the open market, or as otherwise permitted, subject to the normal terms and limitations of such bids. We entered into NCIB ASPPs in each December 2021, June 2022, September 2022, all of which have since expired. At December 31, 2021, we recorded an accrual of $7.5 (2021 NCIB Accrual), representing the estimated Contractual Maximum Quantity (0.7 million SVS) for cancellation under the December 2021 NCIB ASPP, which was reversed in 2022. In each of December 2021 and May 2022, we entered into an SBC ASPP, each of which has since expired. We recorded an accrual as of December 31, 2021 of $33.8 (2021 SBC Accrual), representing the estimated Contractual Maximum Quantity (3.0 million SVS) under the December 2021 SBC ASPP, which was reversed in 2022.
On December 8, 2022, the TSX accepted our notice to launch a new NCIB (2022 NCIB), which allows us to repurchase, at our discretion, from December 13, 2022 until the earlier of December 12, 2023 or the completion of purchases thereunder, up to approximately 8.8 million of our SVS in the open market, or as otherwise permitted, subject to the normal terms and limitations of such bids. As of December 31, 2022, approximately 8.5 million SVS remain available for repurchase under the 2022 NCIB either for cancellation or SBC delivery purposes. In December 2022, we entered into an NCIB ASPP that expired prior to December 31, 2022 (with no accrual recorded).
Information regarding share repurchase activities, including SVS purchases for cancellation under NCIB ASPPs and for SBC plan delivery obligations under SBC ASPPs, for the years indicated is set forth below:
Year ended December 31
202020212022
Aggregate cost (1) of SVS repurchased for cancellation (2)
$0.1 $35.9 $34.6 
  Number of SVS repurchased for cancellation (in millions) (3)
0.0062 4.4 3.4 
  Weighted average price per share for repurchases$7.45 $8.21 $10.45 
Aggregate cost (1) of SVS repurchased for delivery under SBC plans(4)
$19.1 $20.6 $44.9 
  Number of SVS repurchased for delivery under SBC plans (in millions)(5)
2.9 1.9 3.9 
(1)         Includes transaction fees.
(2)     For 2021, excludes the $7.5 2021 NCIB Accrual; for 2020, excludes the $15.0 2020 NCIB Accrual.
(3)    Includes 2.5 million, 2.8 million and nil repurchases of SVS for cancellation under NCIB ASPPs in 2022, 2021 and 2020, respectively.
(4)     For 2021, excludes the $33.8 2021 SBC Accrual.
(5)     Includes 3.9 million, 0.7 million and nil repurchases of SVS for SBC delivery obligations under SBC ASPPs in 2022, 2021 and 2020, respectively.
December 31
202020212022
Number of SVS held by trustee for delivery under SBC plans (1)(2) (in millions)
2.4 1.4 1.5 
Value of SVS held by trustee for delivery under SBC plans (2)
$15.7 $15.1 $16.7 
(1)     For accounting purposes, we classify these shares as treasury stock until they are delivered pursuant to the plans.
(2)     The number and value of SVS held in 2021 exclude the 2021 SBC Accrual.

(b) Employee SBC:
LTIP:
Under the LTIP, we may grant stock options, stock appreciation rights, RSUs and PSUs (Awards) to eligible employees and consultants. Eligible directors may be granted Awards other than stock options. We may, at the time of grant, authorize the grantees to settle these awards either in cash or in SVS. Absent such permitted election, vested grants under the LTIP will be settled in SVS (on a one-for-one basis), either with SVS purchased in the open market or issued from treasury (up to a maximum aggregate of 29.0 million SVS). As of December 31, 2022, 9.9 million SVS remain reserved for issuance from treasury under the LTIP, covering potential issuances of SVS for outstanding awards and for potential future award grants.
Celestica Share Unit Plan (CSUP):
Under the CSUP, we may grant RSUs and PSUs to directors and eligible employees. We have the option to settle vested RSUs and PSUs issued thereunder in SVS (on a one-for-one basis) purchased in the open market, or in cash.
Employee SBC Expense:
Employee SBC expense may fluctuate from period-to-period to account for, among other things, new grants, forfeitures resulting from employee terminations or resignations, and the recognition of accelerated SBC expense for employees eligible for retirement. The portion of employee SBC expense that relates to performance-based compensation is subject to adjustment in any period to reflect changes in the estimated level of achievement of pre-determined performance goals and financial targets. Based on reviews of the status of the non-market performance vesting condition and modifier, we recorded an $8.4 expense reversal in 2020 and a $12.3 expense in 2022 to reflect changes in the estimated number of PSUs expected to vest at the end of January 2021 and at the beginning of February 2023, respectively. No significant adjustments were recorded in 2021 with respect to PSUs expected to vest at the beginning of February 2022.
On December 15, 2022, we entered into the TRS Agreement to manage our cash flow requirements and exposure to fluctuations in the share price of our SVS in connection with the settlement of certain outstanding equity awards under our SBC plans. See notes 2(p) and 20 for further detail.
Information regarding employee SBC expense for the years indicated is set forth below:
Year ended December 31
 202020212022
Employee SBC expense in cost of sales$11.1 $13.0 $20.3 
Employee SBC expense in SG&A14.7 20.4 30.7 
25.8 33.4 51.0 
    For RSUs and DSUs issued to eligible directors under our Directors’ Share Compensation Plan (DSC Plan), see paragraph (c) below.
(i) Stock options:
We are permitted to grant stock options under our LTIP. Stock options are granted at prices equal to the closing market price on the day prior to the grant date and are exercisable during a period not to exceed 10 years from the grant date. Stock option grants and exercises were as follows for the years indicated:
Number of
Options
Weighted Average
Exercise Price*
(in millions)
Outstanding at January 1, 20200.3 $12.50 
Exercised
— $— 
Outstanding at December 31, 20200.3 $12.78 
Granted
0.09 $10.58 
Exercised
(0.02)$6.54 
Outstanding at December 31, 20210.4 $12.70 
Exercised
(0.02)$6.36 
Outstanding at December 31, 20220.4$12.38 
    The following stock options* were outstanding as at December 31, 2022:
Range of Exercise Prices
Outstanding
Options
Weighted Average
Exercise Price
Weighted Average Remaining Life
of Outstanding Options
Exercisable
Options
Weighted Average
Exercise Price
(in millions)(years)(in millions)
$10.58 to $12.93
0.412.384.10.3$12.76
*     The exercise prices were determined by converting the grant date fair value into U.S. dollars at the year-end exchange rate.
We amortize the estimated grant date fair value of stock options to expense over the vesting period (generally 4 years). The grant date fair value of stock options granted in 2021 was determined using the Black-Scholes option pricing model and the following assumptions: risk-free interest rate (based on U.S. government bond yields) of 1.09%, expected volatility of the market price of our shares (based on historical volatility of our share price) of 43%, and the expected option life of 7 years (based on historical option holder behavior). No stock options were granted in 2020 or 2022.
(ii) RSUs and PSUs:
We grant RSUs and PSUs to employees pursuant to our LTIP and CSUP. Each vested unit generally entitles the holder to receive one SVS. Under the CSUP, we have the option to satisfy the delivery of shares upon vesting of the awards by purchasing SVS in the open market or by settling such awards in cash. Under the LTIP, we may (at the time of grant) authorize the grantees to settle awards in either cash or SVS (absent such permitted election, grants will be settled in SVS purchased in the open market or issued from treasury, subject to certain limits). Unless a grantee has been authorized, and elects, to settle these awards in cash, Celestica intends to settle all outstanding RSUs and PSUs with SVS. As a result, we account for these share unit awards as equity-settled awards. We amortize the grant date fair value of RSUs and PSUs to expense over the vesting period.

    The grant date fair value of RSUs is based on the market value of our SVS at the time of grant.
    With respect to PSUs, employees are granted a target number of PSUs (set forth for the years indicated in the table below). The number of PSUs that will actually vest will vary from 0% to 200% of the target amount granted based on the level of achievement of the relevant performance conditions. PSUs (representing in each case 100% of target) are primarily granted in the first quarter of each year. PSUs granted in 2020, 2021 and 2022 vested or will vest based on the level of achievement of a pre-determined non-market performance measurement in the final year of the three-year performance period, subject to modification by each of a separate pre-determined non-market financial target and our relative TSR performance over the three-year vesting period. See note 2(l). The grant date fair value of the TSR modifier is based on a Monte Carlo simulation model and a premium of 116% for 2022 (2021 — 109%; 2020 — 112%). The grant date fair value of the non-TSR-based performance measurement and modifier is based on the market value of our SVS at the time of grant and
is subject to adjustment to reflect changes in the estimated level of achievement related to the applicable performance condition. Vested awards were settled with SVS purchased in the open market by a broker, or issued from treasury.
The assumptions used in the measurement of the grant date fair values of PSUs were as follows:
Year ended December 31
202020212022
Expected volatility30 %49 %52 %
Expected life 3 years3 years3 years
Risk-free interest rate (based on 3-year Treasury bonds)1.4 %0.2 %1.4 %
    Information regarding aggregate RSU, PSU and stock option grants to employees, as applicable, for the years indicated is set forth below:
Year ended December 31
 202020212022
RSUs Granted:
Number of awards (in millions)2.4 3.0 2.0 
Weighted average grant date fair value per unit$8.60 $8.36 $12.17 
PSUs Granted:
Number of awards (in millions, representing 100% of target)
1.7 2.9 1.3 
Weighted average grant date fair value per unit$9.88 $9.49 $14.27 
Stock Options Granted:
Number of awards (in millions)— 0.09 — 
Weighted average grant date fair value per option$— $4.22 $— 
December 31
202020212022
Number of outstanding RSUs (in millions)4.5 4.6 3.8 
Number of outstanding PSUs (in millions, representing 100% of target granted)
4.6 6.1 5.1 
(c) Director SBC:
    We grant DSUs to certain members of our Board of Directors and Onex under our DSC Plan. We also grant RSUs (under specified circumstances) to certain directors as compensation under the DSC Plan. RSUs granted to directors vest ratably over a three-year period and are governed by the terms of our LTIP. Each vested RSU entitles the holder thereof to one SVS; however, if permitted by the Company under the terms of the grant, a director may elect to receive a payment of cash in lieu of SVS. Unvested RSUs vest immediately on the date the director Retires. See note 2(l) for additional detail. As Celestica is permitted to, and intends to, settle DSUs with shares purchased in the open market, we account for these awards as equity-settled awards. On January 29, 2020, William A. Etherington retired from Celestica’s Board of Directors. In accordance with the DSC Plan, the DSUs held by Mr. Etherington will be redeemed on or prior to the 90th day following the date on which he is no longer a director or employee of any corporation that does not deal at arm’s length with the Company. As of December 31, 2022, Mr. Etherington held 0.475 million DSUs as he remained as a director of Onex. Eamon Ryan retired from Celestica's Board of Directors in April 2022. The 0.03 million RSUs then-held by Mr. Ryan were vested and settled upon his retirement. In accordance with the DSC Plan, the 0.26 million DSUs then-held by Mr. Ryan were settled in July 2022.
    Information regarding director SBC expense for the years indicated is set forth below:
Year ended December 31
202020212022
Director SBC expense in SG&A (1)
$2.0 $2.1 $2.2 
DSUs Granted:
Number of awards (in millions)0.2 0.12 0.12 
Weighted average grant date fair value per unit$5.64 $8.98 $10.18 
RSUs Granted:
Number of awards (in millions)0.022 0.054 0.042 
Weighted average grant date fair value per unit$5.71 $8.92 $10.44 
December 31
202020212022
Number of DSUs outstanding (in millions)2.0 2.2 2.1 
Number of RSUs issued to directors outstanding (in millions)0.03 0.07 0.07 
(1)    Expense consists of director compensation to be settled with SVS, or SVS and cash, as elected by each director.